3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
NET
1
Gynecologic
1
Endocrine
1
Conditions
Ovarian Neoplasms
507
Uterine Cervical Neoplasms
361
Endometrial Neoplasms
304
Breast Neoplasms
128
Colorectal Neoplasms
112
Neoplasms
98
Fallopian Tube Neoplasms
90
Carcinoma, Non-Small-Cell Lung
87
Stomach Neoplasms
83
Pancreatic Neoplasms
79
Lung Neoplasms
72
Melanoma
68
Prostatic Neoplasms
66
Carcinoma, Ovarian Epithelial
65
Neoplasm Metastasis
63
Triple Negative Breast Neoplasms
51
Vulvar Neoplasms
49
Squamous Cell Carcinoma of Head and Neck
49
Head and Neck Neoplasms
45
Esophageal Neoplasms
43
Uterine Neoplasms
40
Peritoneal Neoplasms
40
Urinary Bladder Neoplasms
38
Carcinoma, Hepatocellular
35
Carcinoma, Renal Cell
34
Uterine Cervical Dysplasia
31
Papillomavirus Infections
31
Colonic Neoplasms
31
Sarcoma
30
Recurrence
29
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Anal Canal Carcinoma
×
Gynecologic
×
Clear all
NCT06640283
2025-12-24
ANA
Instituto do Cancer do Estado de São Paulo
Phase 2
Recruiting
150 enrolled